Uveitis bei multipler Sklerose

Adamus G, Burrows GG, Vandenbark AA et al (2006) Treatment of autoimmune anterior uveitis with recombinant TCR ligands. Invest Ophthalmol Vis Sci 47:2555–2561 Arnold AC, Pepose JS, Hepler RS et al (1984) Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics. Ophthalmology 91:255–262 Beck RW, Trobe JD, Moke PS et al (2003) High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 121:944–949 Beyer AM, Rosche B, Pleyer U et al (2007) The role of uveitis in demyelinating diseases of the central nervous system. Nervenarzt 78:1389–1398 Biousse V, Trichet C, Bloch-Michel E et al (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52:179–181 Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415 Donaldson MJ, Pulido JS, Herman DC et al (2007) Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol 144:812–817 Fernandez O, Fernandez V, De Ramon E (2004) Azathioprine and methotrexate in multiple sclerosis. J Neurol Sci 223:29–34 Gorczyca WA, Ejma M, Witkowska D et al (2004) Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis. Ophthalmic Res 36:120–123 Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111:491–500 Heinz C, Heiligenhaus A (2007) Improvement of noninfectious uveitis with fumaric acid esters: results of a pilot study. Arch Ophthalmol 125:569–571 Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513 Jain N, Bhatti MT (2012) Fingolimod-associated macular edema: incidence, detection, and management. Neurology 78:672–680 Jakob E, Reuland MS, Mackensen F et al (2009) Uveitis subtypes in a german interdisciplinary uveitis center – analysis of 1916 patients. J Rheumatol 36:127–136 Kalina PH, Pach JM, Buettner H et al (1990) Neovascularization of the disc in pars planitis. Retina 10:269–273 Kappos L, Antel J, Comi G et al (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124–1140 Kempen JH, Ganesh SK, Sangwan VS et al (2008) Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol 146:813–818 e811 Kurose S, Ikeda E, Tokiwa M et al (2000) Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res 70:7–15 Mackensen F, Jakob E, Springer C et al (2013) Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 156:478–486 e471 Malinowski SM, Pulido JS, Folk JC (1993) Long-term visual outcome and complications associated with pars planitis. Ophthalmology 100:818–824 Malinowski SM, Pulido JS, Goeken NE et al (1993) The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology 100:1199–1205 Michel L, Vukusic S, De Seze J et al (2013) Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry 85:279–283 Nicholas J, Morgan-Followell B, Pitt D et al (2012) New and emerging disease-modifying therapies for relapsing-remitting multiple sclerosis: what is new and what is to come. J Cent Nerv Syst Dis 4:81–103 Nussenblatt RB, Palestine AG, Chan CC et al (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92:467–471 Nussenblatt RB, Peterson JS, Foster CS et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112:764–770 Oh J, O’Connor PW (2013) Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs 27:591–609 Okada AA, Keino H, Fukai T et al (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:215–226 Ortiz-Perez S, Martinez-Lapiscina EH, Gabilondo I et al (2013) Retinal periphlebitis is associated with multiple sclerosis severity. Neurology 81:877–881 Raja SC, Jabs DA, Dunn JP et al (1999) Pars planitis: clinical features and class II HLA associations. Ophthalmology 106:594–599 Raveney BJ, Copland DA, Nicholson LB et al (2008) Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease. Arch Ophthalmol 126:1390–1395 Rucker CW (1972) Sheathing of the retinal veins in multiple sclerosis. Review of pertinent literature. Mayo Clin Proc 47:335–340 Sepulcre J, Murie-Fernandez M, Salinas-Alaman A et al (2007) Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 68:1488–1494 Thacker EL, Mirzaei F, Ascherio A (2006) Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 59:499–503 Valentincic NV, Kraut A, Rothova A (2007) Vitreous hemorrhage in multiple sclerosis-associated uveitis. Ocul Immunol Inflamm 15:19–25 Younge BR (1976) Fluorescein angiography and retinal venous sheathing in multiple sclerosis. Can J Ophthalmol 11:31–36 Zarbin MA, Jampol LM, Jager RD et al (2013) Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 120:1432–1439